Abstract：Objective: To study the effect of pidotimod in treatment of children with hand-foot disease and its effects on T lymphocyte subsets and inflammatory factors. Methods: 800 children with hand-foot-mouth disease admitted to Xi'an Children's Hospital were divided into observation group and control group according to the order of admission, 400 cases in each group. The control group was treated with ribavirin, and the observation group was treated with pidotimod. The herpes elimination time, body temperature return time, hospital stay, T-lymphocyte subsets, inflammatory factors, and immunoglobulin were compared between the two groups. Results: The herpes elimination time, normal body temperature return time, and length of stay in the observation group were significantly less than those in the control group (P<0.05). Before treatment, there was no significant difference in the CD3+, CD4+, CD8+, and ratios of CD4+/CD8+ cells between the two groups (P>0.05). After treatment, the CD3+, CD4+, CD8+, and ratios of CD4+/CD8+ cells in the observation group were significantly higher than those in the control group(P<0.05). Before treatment, there was no significant difference in the levels of IL-6, IL-10, IL-1β and TNF-α between the two groups (P>0.05). After treatment, the levels of IL-6, IL-1β and TNF-α in the observation group were significantly lower than the control group (P<0.05), IL-10 levels were significantly higher than the control group (P<0.05). Before treatment, the levels of IgA, IgG, and IgM in the two groups were not significantly different (P>0.05). The IgA and IgG levels in the observation group were significantly higher than those in the control group (P<0.05). Conclusion: Pidotimod adjuvant therapy can effectively improve T lymphocyte immune function and inflammatory factors in children with hand-foot and mouth disease, and promote the recovery of children disease, with good clinical efficacy.
张进军,吴胜会,刘科贝. 匹多莫德辅助治疗对手足口病患儿T淋巴细胞亚群和炎症因子的影响[J]. 河北医学, 2018, 24(12): 1973-1977.
ZHANG Jinjun, WU Shenghui, LIU Kebei. Effect of Pidotimod Adjuvant Therapy on T lymphocyte Subsets and Inflammatory Factors in Children with Hand Foot Mouth Disease. HeBei Med, 2018, 24(12): 1973-1977.
[1] Anh NT , Nhu LNT , Van HMT , et al. Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam[J]. Emerging Infectious Diseases, 2018,24(4):654~662. [2] Sun JF , Li HL , Sun BX . Correlation analysis on serum inflammatory cytokine level and neurogenic pulmonary edema for children with severe hand-foot-mouth disease[J]. European Journal of Medical Research, 2018, 23 (1):21. [3] 雷春霞,王石.匹多莫德联合孟鲁司特钠治疗儿童支气管哮喘的临床观察[J].中国药房,2016,27(29):4142~4144. [4] 中华人民共和国卫生部.2008年手足口病预防控制指南[J].中华实验和临床感染病杂志,2008,2:210. [5] Tian L , Liang F , Xu M ,et al. Spatio-temporal analysis of the relationship between meteorological factors and hand-foot-mouth disease in Beijing, China[J]. BMC Infectious Diseases, 2018,18 (1):158. [6] 袁媛,刘鑫,周娅,等.重组EV71和CVA16型手足口病双价VLP疫苗构建及免疫保护效果评价[J].免疫学杂志,2014,30(6):469~473. [7] 汤昔康,李庆彦,李汝霞,等.手足口病合并细菌感染的临床特征与免疫功能变化研究[J].中华医院感染学杂志,2016,26(20):4721~4723,4762. [8] 蔡晓华.匹多莫德对支气管哮喘患儿免疫功能的影响及疗效分析[J].重庆医学,2014,43(12):1508~1511.
2018, Vol. 24 
冀公网安备13080202000677号